Cardiac Troponin Measurement in the Critically Ill: Potential for Guiding Clinical Management

Stacy Poe, Robin H Vandivier-Pletsch, Michael Clay, Hector R Wong, Erin Haynes, Florence G Rothenberg, Stacy Poe, Robin H Vandivier-Pletsch, Michael Clay, Hector R Wong, Erin Haynes, Florence G Rothenberg

Abstract

Background: Elevated cardiac troponin (cTn) in the absence of acute coronary syndromes (ACS) is associated with increased mortality in critically ill patients. There are no evidence-based interventions that reduce mortality in this group.

Objectives: We performed a retrospective investigation of the Veterans Administration Inpatient Evaluation Center database to determine whether drugs used in ACS (β-blockers, aspirin, and statins) are associated with reduced mortality in critically ill patients.

Methods: Thirty-day mortality was determined for non-ACS patients admitted to any Veterans Administration Intensive Care Unit between October 1, 2007, and September 30, 2008, adjusted for severity of illness. Troponin assay values were normalized across institutions.

Results: Multivariate analyses for 30-day mortality showed an odds ratio (OR) of 1.82 for patients with high cTn (P < 0.0001, cTn > 10% coefficient of variation) and 1.18 for intermediate cTn (P = 0.0021, cTn between lowest limit detectable and 10% coefficient of variation) compared with patients with no elevation, adjusting for severity of illness (n = 19,979). Logistic regression models showed that patients with no or intermediate elevations of cTn taking statins within 24 hours of cTn measurement had a lower mortality than patients not taking statins (OR, 0.66; 95% confidence interval [95% CI], 0.53-0.82; P = 0.0003), whereas patients with high cTn had a lower mortality if they were taking β-blockers or aspirin within 24 hours of cTn measurement compared to patients not taking β-blockers or aspirin (β-blockers: OR, 0.80; 95% CI, 0.68-0.94; P = 0.0077; aspirin: OR, 0.81;95% CI, 0.69-0.96; P = 0.0134).

Conclusions: This retrospective study confirms an association between elevated troponin and outcomes in critically ill patients without ACS and identifies statins, β-blockers, and aspirin as potential outcome modifiers in a cTn-dependent manner.

Figures

FIGURE 1
FIGURE 1
Branching algorithm describing VA-IPEC ICU patient population October 2007 to September 2008.
FIGURE 2
FIGURE 2
Distribution of primary diagnoses admitted to VA ICUs October 2007 to September 2008 (n = 19,979).
FIGURE 3
FIGURE 3
Relationship between 30-day mortality and troponin level: no cTn elevation, 10.7% 30-day mortality; intermediate cTn, 16.6% 30-day mortality; high cTn, 31.7% 30-day mortality.
FIGURE 4
FIGURE 4
Measurement of cTn in critically ill patients may help guide potentially life-saving therapy.

References

    1. Ammann P, Maggiorini M, Bertel O, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol. 2003; 41: 2004– 2009.
    1. John J, Woodward DB, Wang Y, et al. Troponin-I as a prognosticator of mortality in severe sepsis patients. J Crit Care. 2010; 25: 270– 275.
    1. Reynolds T, Cecconi M, Collinson P, et al. Raised serum cardiac troponin I concentrations predict hospital mortality in intensive care unit patients. Br J Anaesth. 2012; 109: 219– 224.
    1. Stein R, Gupta B, Agarwal S, et al. Prognostic implications of normal (<0.10 ng/ml) and borderline (0.10 to 1.49 ng/ml) troponin elevation levels in critically ill patients without acute coronary syndrome. Am J Cardiol. 2008; 102: 509– 512.
    1. Vasile VC, Chai HS, Abdeldayem D, et al. Elevated cardiac troponin T levels in critically ill patients with sepsis. Am J Med. 2013; 126: 1114– 1121.
    1. Ammann P, Fehr T, Minder EI, et al. Elevation of troponin I in sepsis and septic shock. Intensive Care Med. 2001; 27: 965– 969.
    1. Martin M, Mullenix P, Rhee P, et al. Troponin increases in the critically injured patient: mechanical trauma or physiologic stress? J Trauma. 2005; 59: 1086– 1091.
    1. Hassan B, Morsy S, Siam A, et al. Myocardial injury in critically ill children: a case control study. ISRN Cardiol. 2014; 2014: 919150.
    1. Hamilton MA, Toner A, Cecconi M. Troponin in critically ill patients. Minerva Anestesiol. 2012; 78: 1039– 1045.
    1. Alpert JS, Thygesen KA, White HD, et al. Diagnostic and therapeutic implications of type 2 myocardial infarction: review and commentary. Am J Med. 2014; 127: 105– 108.
    1. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012; 60: 1581– 1598.
    1. Render ML, Welsh DE, Kollef M, et al. Automated computerized intensive care unit severity of illness measure in the Department of Veterans Affairs: preliminary results. SISVistA Investigators. Scrutiny of ICU Severity Veterans Health Systems Technology Architecture. Crit Care Med. 2000; 28: 3540– 3546.
    1. Render ML, Kim HM, Welsh DE, et al. ; VA ICU Project (VIP) Investigators. Automated intensive care unit risk adjustment: results from a National Veterans Affairs study. Crit Care Med. 2003; 31: 1638– 1646.
    1. Render ML, Kim HM, Deddens J, et al. Variation in outcomes in Veterans Affairs intensive care units with a computerized severity measure. Crit Care Med. 2005; 33: 930– 939.
    1. Render ML, Deddens J, Freyberg R, et al. Veterans Affairs intensive care unit risk adjustment model: validation, updating, recalibration. Crit Care Med. 2008; 36: 1031– 1042.
    1. Lim W, Cook DJ, Griffith LE, et al. Elevated cardiac troponin levels in critically ill patients: prevalence, incidence, and outcomes. Am J Crit Care. 2006; 15: 280– 288.
    1. Babuin L, Vasile VC, Rio Perez JA, et al. Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients. Crit Care Med. 2008; 36: 759– 765.
    1. Salim A, Hadjizacharia P, Brown C, et al. Significance of troponin elevation after severe traumatic brain injury. J Trauma. 2008; 64: 46– 52.
    1. Vasile VC, Chai HS, Khambatta S, et al. Significance of elevated cardiac troponin T levels in critically ill patients with acute respiratory disease. Am J Med. 2010; 123: 1049– 1058.
    1. Tiruvoipati R, Sultana N, Lewis D. Cardiac troponin I does not independently predict mortality in critically ill patients with severe sepsis. Emerg Med Australas. 2012; 24: 151– 158.
    1. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996; 335: 1342– 1349.
    1. Klouche K, Jonquet O, Cristol JP. The diagnostic challenge of myocardial infarction in critically ill patients: do high-sensitivity troponin measurements add more clarity or more confusion? Crit Care. 2014; 18: 148.
    1. de Lemos JA. Increasingly sensitive assays for cardiac troponins: a review. JAMA. 2013; 309: 2262– 2269.
    1. Ostermann M, Forni LG. Measuring biomarkers of acute kidney injury during renal replacement therapy: wisdom or folly? Crit Care. 2014; 18: 155.
    1. Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013; 310: 1683– 1691.
    1. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993; 270: 2957– 2963.
    1. Otto GP, Sossdorf M, Boettel J, et al. Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock. Platelets. 2013; 24: 480– 485.
    1. Sossdorf M, Otto GP, Boettel J, et al. Benefit of low-dose aspirin and non-steroidal anti-inflammatory drugs in septic patients. Crit Care. 2013; 17: 402.
    1. Thomas G, Hraiech S, Loundou A, et al. Statin therapy in critically-ill patients with severe sepsis: a review and meta-analysis of randomized clinical trials. Minerva Anestesiol. 2015; 81: 921– 930.
    1. Tralhão AF, Cés de Souza-Dantas V, Salluh JI, Póvoa PM. Impact of statins in outcomes of septic patients: a systematic review. Postgrad Med. 2014; 126: 45– 58.
    1. Patel JM, Snaith C, Thickett DR, et al. Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit Care. 2012; 16: R231.
    1. American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions, O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61: e78– e140.
    1. 2012 Writing Committee Members, Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2012; 126: 875– 910.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다